Usage of Heberprot-P® in Patients with Diabetic Foot Ulcer

Abstract

Introduction: Diabetic foot ulcer is a common complication in diabetic patients. Amputations are a major health problem, which generates a high cost for the patient, their relatives and public health systems.

Objective: To evaluate the outcomes of treatment with Heberprot-P^® in patients with diabetic foot ulcer.

Methods: An observational, descriptive, prospective, prospective and longitudinal pharmaco-epidemiological study was carried out in patients with a diagnosis of diabetic foot ulcer and who attended the angiology and vascular surgery service of Hospital Enrique Cabrera, during the period from January 2022 to August 2023.

Results: The most represented sex was female, with diabetes mellitus II: 48.44 % being grade 3. Regarding age, 45.32 % were between 60 and 69 years old. Most of the patients had vascular diseases. According to the McCook etiopathogenic classification, neuroinfectious diabetic foot was the most frequent. More patients were affected on the right foot, while there were more cases on the sole and toes. Debridement was the main cause of surgical intervention.

Conclusions: Satisfactory outcomes, obtained mainly after 15 days of stay, were significant.